Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals

Rev Esp Enferm Dig. 2019 Feb;111(2):159-161. doi: 10.17235/reed.2018.5528/2018.

Abstract

The use of direct-acting antivirals (DAA) for the hepatitis C virus (HCV) has yielded a significant improvement in the treatment of autoimmune hepatitis (AIH) associated with HCV infection. Interferon was the cornerstone of HCV therapy before the introduction of these agents into the clinical practice. Herein, we report the case of an HCV-infected patient who developed an interferon-induced AIH and since then, has received immunosuppressive therapy. Administration of DAA resulted in a sustained virologic response (SVR) and clinical AIH remission which allowed a discontinuation of immunosuppressive treatment.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Azathioprine / therapeutic use
  • Benzimidazoles / therapeutic use
  • Female
  • Fluorenes / therapeutic use
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis, Autoimmune / drug therapy*
  • Hepatitis, Autoimmune / etiology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interferons / adverse effects
  • Middle Aged
  • Prednisone / therapeutic use
  • Sofosbuvir
  • Sustained Virologic Response
  • Uridine Monophosphate / analogs & derivatives
  • Uridine Monophosphate / therapeutic use

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • Immunosuppressive Agents
  • ledipasvir, sofosbuvir drug combination
  • Interferons
  • Uridine Monophosphate
  • Azathioprine
  • Prednisone
  • Sofosbuvir